Bank of New York Mellon Corp boosted its position in shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) by 37.1% during the first quarter, Holdings Channel reports. The institutional investor owned 59,841 shares of the company’s stock after buying an additional 16,191 shares during the period. Bank of New York Mellon Corp’s holdings in Neos Therapeutics were worth $431,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Teachers Advisors LLC raised its stake in Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock worth $149,000 after buying an additional 3,572 shares in the last quarter. Sheaff Brock Investment Advisors LLC purchased a new stake in Neos Therapeutics during the first quarter worth approximately $216,000. Wells Fargo & Company MN raised its stake in Neos Therapeutics by 130.3% in the first quarter. Wells Fargo & Company MN now owns 48,030 shares of the company’s stock worth $346,000 after buying an additional 27,174 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Neos Therapeutics during the fourth quarter worth approximately $545,000. Finally, Falcon Point Capital LLC raised its stake in Neos Therapeutics by 3.1% in the first quarter. Falcon Point Capital LLC now owns 88,279 shares of the company’s stock worth $636,000 after buying an additional 2,691 shares in the last quarter. 33.71% of the stock is owned by institutional investors.

Neos Therapeutics, Inc. (NASDAQ:NEOS) opened at 6.70 on Friday. Neos Therapeutics, Inc. has a one year low of $4.85 and a one year high of $9.60. The stock has a 50 day moving average price of $7.22 and a 200-day moving average price of $6.94. The firm’s market cap is $151.15 million.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Tuesday, May 9th. The company reported ($0.87) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.94) by $0.07. Neos Therapeutics had a negative return on equity of 512.10% and a negative net margin of 719.86%. The business had revenue of $5.63 million for the quarter. Analysts predict that Neos Therapeutics, Inc. will post ($3.15) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/05/bank-of-new-york-mellon-corp-has-431000-position-in-neos-therapeutics-inc-nasdaqneos.html.

A number of analysts have commented on the stock. Cantor Fitzgerald assumed coverage on shares of Neos Therapeutics in a research note on Monday, July 31st. They set an “overweight” rating and a $20.00 price objective for the company. Zacks Investment Research lowered shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 27th. BMO Capital Markets reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Neos Therapeutics in a research note on Tuesday, June 20th. Finally, ValuEngine raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $14.40.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics, Inc. (NASDAQ:NEOS).

Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.